Thermo Fisher flashes the Covid cash
The $2.6bn acquisition of The Binding Site is 2022’s biggest medtech deal, but investors are unmoved.
Covid-19 tests versus Omicron
The new variant might be able to dodge one of the PCR tests authorised in the US, the FDA says.
Diasorin heads to the US with $1.8bn Luminex deal
And consolidation in the diagnostics space is only just beginning.
Medtech’s haves and have-nots
Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.